Skip to main content

Table 1 The blood routine results of grouped rats (n = 6) 150 μl Freund’s complete adjuvant was injected into the left hind toe of male SD rats for 20 days to build AA model group while control groups were treated with 150 μl physiological saline in the same parts

From: Resveratrol reduces store-operated Ca2+ entry and enhances the apoptosis of fibroblast-like synoviocytes in adjuvant arthritis rats model via targeting ORAI1–STIM1 complex

Names Units Control Model 45 mg Res 45 mg Res+Orai1 Orai1-SiRNA 200 mg/kg NAC
Red blood cell (RBC) 1012/L 6.94  ±  1.02 7.16 ± 0.94 7.03 ± 1.03 6.94 ± 1.12 7.11 ± 1.03 7.31 ± 0.97
Hemoglobin (HGB) g/L 146 ± 7.6 149 ± 8.9 142 ± 6.4 156 ± 11.2 153 ± 9.8 152 ± 10.5
Mean corpuscular hemoglobin (MCH) pg 21.4 ± 0.59 18.9 ± 0.49* 20.3 ± 0.42# 19.3 ± 0.56 19.1 ± 0.48# 19.2 ± 0.46*
Mean corpuscular hemoglobin concentration (MCHC) g/L 331 ± 8.92 325 ± 8.72 334 ± 9.23 332 ± 9.12 328 ± 8.92 327 ± 9.35
Hematocrit (HCT) % 46 ± 2.68 45 ± 2.74 44 ± 3.02 47 ± 2.93 43 ± 2.82 45 ± 2.72
Mean corpuscular volume (MCV) fL 66.12 ± 1.2 61.28 ± 1.02* 64.31 ± 1.62# 63.45 ± 1.03 62.58 ± 1.03# 65.32 ± 1.49*
Platelet (PLT) 109/L 858.23 ± 256.62 764.32 ± 264.54 792.64 ± 278.38 821.61 ± 248.78 785.23 ± 345.65 862.67 ± 292.82
Mean platelet volume (MPV) fL 8.15 ± 1.45 7.96 ± 1.62 7.45 ± 0.98 7.64 ± 1.03 8.35 ± 1.14 8.27 ± 1.23
Thrombocytocrit (PCT) % 0.62 ± 0.08 0.58 ± 0.06 0.54 ± 0.07 0.65 ± 0.12 0.61 ± 0.09 0.58 ± 0.11
Platelet distribution width (PDW) % 8.64 ± 1.23 9.45 ± 1.64 8.67 ± 1.15 9.26 ± 1.65 8.94 ± 1.98 8.92 ± 1.52
Large platelet ratio (P-LCR) % 11.75 ± 2.23 9.11 ± 1.98 9.85 ± 2.78 11.26 ± 1.84 10.54 ± 2.12 11.56 ± 2.36
White blood cell (WBC) 109/L 12.65 ± 1.62 18.44 ± 1.54* 14.3 ± 1.78# 16.5 ± 1.23 18.1 ± 0.98# 13.4 ± 1.56*
Neutrophil (NEUT) 109/L 1.41 ± 0.27 5.28 ± 1.36* 2.20 ± 0.58# 3.06 ± 0.56 2.27 ± 0.32# 1.80 ± 0.24*
Percentage of neutrophils (%) 11.2 ± 2.92 28.65 ± 4.68* 15.4 ± 2.65# 18.56 ± 3.46 12.56 ± 2.42# 13.5 ± 2.65*
Lymphocyte (LYMPH) 109/L 8.12 ± 1.78 15.54 ± 2.02* 10.04 ± 1.89# 12.78±2.02 14.73±2.56# 9.18±1.52*
Percentage of lymphocyte % 64.26±4.23 84.32±5.56* 70.23±4.59# 77.5 ± 5.21 81.4 ± 4.21# 68.56 ± 5.96*
Monocyte (MONO) 109/L 0.62 ± 0.07 0.96 ± 0.12* 0.67 ± 0.08# 0.75 ± 0.07 0.89 ± 0.11# 0.72 ± 0.06*
Percentage of monocyte % 4.90 ± 0.98 5.20 ± 1.02* 4.68 ± 0.95# 4.54 ± 1.06 4.91 ± 0.85# 5.37 ± 1.05*
Eosinophils (EO) 109/L 0.08 ± 0.01 0.1 ± 0.02 0.09 ± 0.01 0.11 ± 0.03 0.11 ± 0.02 0.09 ± 0.03
Percentage of eosinophils % 0.63 ± 0.12 0.54 ± 0.16 0.62 ± 0.13 0.66 ± 0.14 0.60 ± 0.09 0.67 ± 0.11
  1. All the animals were divided into 6 groups including control group, AA model group and other 4 drug intervention groups in which remaining model rats were respectively treated with 45 mg/kg, 45 mg/kg resveratrol + ORAI-1 overexpressed vector, ORAI-1 SiRNA and 200 mg/kg NAC for 12 days by intragastric administration and joint cavity microinjection with 10 rats/group. whole blood samples were extracted via eye ball removal assay and immediately received blood routine test. Results were presented as mean±SD. All datasets were analyzed using one-way analysis of variance followed by Tukey's post hoc test to compare the differential significance between each two groups
  2. *P < 0.05, vs Control group; #P < 0.05, vs Model group; P < 0.05, vs 45 mg Res group (down regulation); P < 0.05, vs 45 mg Res group (up regulation)